Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
115.00    3.50 (3.14%)
Bid:
112.00
Ask:
118.00
Spread: 6.00 (5.357%)
Market Cap: £69.19m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

First Customer: Derived Credentials for Mobile

29 Sep 2014 07:00

RNS Number : 8014S
Intercede Group PLC
29 September 2014
 

INTERCEDE GROUP PLC

("Intercede or the "Company")

PRESS RELEASE

29 September 2014

First Customer: Derived Credentials for Mobile

 

Existing Intercede customer to use latest release of MyID credential management softwareto meet new US Government FIPS 201-2 security standard

 

 

Leading digital identity expert Intercede today announced that a high-profile US federal government agency has placed an initial order for its MyID v10.1 credential management software to provide its employees with secure identity on mobile devices to meet the new FIPS 201-2 standard.

 

Launched earlier this month, MyID v10.1 is the US's first derived credential solution that can securely issue and manage trusted personal identity verification (PIV) credentials for mobile. Meeting the technical and business process standards for FIPS 201-2 compliance, MyID combines technology independence with an easy "mobile first" self-service interface to enable fast enterprise-wide deployment of derived credentials.

 

The use of derived credentials enables federal employees to securely access mobile resources that they could previously only get to with their PIV smart card, leading to higher productivity while strengthening security.

 

Richard Parris, Intercede CEO, commented: "This launch customer for MyID v10.1 is the first deployment of a derived credentials based identity solution within the US federal government. Such is our industry leadership that this order was secured even before FIPS 201-2 has been formally ratified. With several more contracts in the pipeline for early closure, we look forward to a healthy new revenue stream from our move into mobile security."

 

Enquiries

 

Intercede Group plcTel. +44 (0)1455 558111Richard Parris, Chairman & Chief ExecutiveAndrew Walker, Finance Director

 

finnCap LtdTel. +44 (0)207 220 0500Stuart Andrews, Corporate FinanceJoanna Weaving, Corporate Broking

 

Bell PottingerTel. +44 (0)7802 442486Archie Berens

 

 

About Intercede

Intercede is a software company specialising in identity and credential management with a global team of experts located in the US and UK.

Intercede's MyID software enables organisations to create and use trusted digital identities for employees, citizens and machines. This allows secure access to services, facilities, information and networks.

MyID meets the highest government standards yet is simple enough to be deployed onto consumer devices such as smartphones and tablets. Critically, MyID provides an easy, convenient and secure alternative to passwords.

Millions of identities are managed using MyID and Intercede has provided identity verification and management services to global customers for more than twenty years. MyID is a commercial-off-the-shelf software product, designed and developed to be configurable so it can be embedded as the cornerstone of cybersecurity infrastructure for governments and corporations.

Customers trusting Intercede for secure digital identity include the US and UK governments and some of the world's largest corporations, telecommunications providers and information technology partners.

For more information visit: www.intercede.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAFVLLLZKFLBBZ
Date   Source Headline
20th Jul 20217:00 amRNSIntercede achieves FIDO2 certification
5th Jul 20217:00 amRNSConnect Partner Programme & Q1 Contract Wins
15th Jun 20218:26 amRNSIssue of Equity
8th Jun 20217:00 amRNSFinal Results
2nd Jun 202110:09 amRNSInvestor Presentation
10th May 20217:00 amRNSShare Incentive Plan
7th Apr 20217:00 amRNSTrading Update & Appointment of Auditor
1st Apr 202110:30 amRNSReceipt of $3.4m Order
10th Mar 20217:00 amRNSShare Incentive Plan
23rd Feb 20217:00 amRNSAmendment to LTIP
22nd Feb 20214:10 pmRNSHolding(s) in Company
16th Feb 20217:00 amRNSCLN Conversion to Equity
12th Feb 20217:00 amRNSHolding(s) in Company
8th Feb 202112:40 pmRNSHolding(s) in Company
4th Feb 20217:00 amRNSCLN Call & Issue of Equity
11th Jan 20217:00 amRNSNew Contract Win
5th Jan 202111:00 amRNSCLN Conversion to Equity
4th Jan 202110:40 amRNSHolding(s) in Company
22nd Dec 20207:00 amRNSNew Contract Win
24th Nov 20207:00 amRNSHalf-year Report
17th Nov 20207:00 amRNSContract Win: Follow-on Purchase Order
12th Nov 20207:00 amRNSInvestor Presentation
8th Oct 20207:01 amRNSIntercede join the FIDO Alliance
8th Oct 20207:00 amRNSTrading Update
16th Sep 20203:40 pmRNSResult of AGM
20th Aug 20207:05 amRNSContract Win - Initial Progress Order
5th Aug 20202:01 pmRNSHolding(s) in Company
30th Jul 20207:00 amRNSContract Win
2nd Jun 20207:00 amRNSFinal Results
12th May 20207:00 amRNSShare Incentive Plan
20th Apr 202010:02 amRNSDirector/PDMR Shareholding
14th Apr 20207:00 amRNSDirector/PDMR Shareholding
7th Apr 20207:00 amRNSTrading Update
3rd Apr 20205:07 pmRNSShare Incentive Plan
31st Mar 20207:00 amRNSReceipt of $4.6m Order
28th Feb 20207:00 amRNSShare Incentive Plan
26th Feb 20209:50 amRNSShare Incentive Plan
25th Feb 20207:00 amRNSShare Incentive Plan
12th Feb 202011:22 amRNSShare Award
25th Nov 20197:00 amRNSHalf-year Report
7th Oct 20197:00 amRNSTrading Update
30th Sep 20197:00 amRNSDirector/PDMR Shareholding
18th Sep 20196:30 pmRNSResult of AGM
16th Sep 20193:56 pmRNSPosting of Annual Report & Notice of AGM
17th Jun 20197:00 amRNSAppointment of Non-Executive Director
5th Jun 20197:00 amRNSFinal Results
8th Apr 20197:00 amRNSSale of Property
2nd Apr 20197:00 amRNSTrading Update
28th Feb 20197:00 amRNSNew Contract Win
4th Feb 20193:19 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.